Evidence map›Paper›PMID 41407727›Full record

ArticleNature communications2025

Enantioselective protein affinity selection mass spectrometry (E-ASMS).

Xiaoyun Wang, Jianxian Sun, Shabbir Ahmad, Diwen Yang, Fengling Li, U Hang Chan, Hong Zeng, Conrad V Simoben, Stuart R Green, Madhushika Silva and 29 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

39 authors.

Xiaoyun Wang *Department of Chemistry, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-7410-0667
Jianxian Sun *Department of Chemistry, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-0385-9959
Shabbir Ahmad *Structural Genomics Consortium, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-2374-1197
Diwen YangDepartment of Physical & Environmental Sciences, University of Toronto Scarborough, Toronto, ON, Canada.
Fengling LiStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.
U Hang ChanStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.
Hong ZengStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.
Conrad V SimobenStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-5958-6961
Stuart R GreenStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-2960-9683
Madhushika SilvaStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0009-0001-7060-0445
Scott HoulistonPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Aiping DongStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.
Albina BolotokovaStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.
Elisa GibsonStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-7112-337X
Maria KuteraStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.
Pegah GhiabiStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.
Ivan KondratovEnamine Ltd., Kyiv, Ukraine.
Tetiana MatviyukEnamine Ltd., Kyiv, Ukraine.
Alexander ChuprinaEnamine Ltd., Kyiv, Ukraine.
Danai MavridiInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID http://orcid.org/0009-0004-7379-9527
Christopher LenzInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID http://orcid.org/0009-0000-2261-2823
Andreas C JoergerInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID http://orcid.org/0000-0002-1232-0138
Benjamin D BrownBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Richard B HeathBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Wyatt W YueBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID http://orcid.org/0000-0001-6959-6007
Lucy K RobbieEmory University School of Medicine, Atlanta, GA, USA.
Tyler S BeyettEmory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-5509-7004
Susanne MüllerInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID http://orcid.org/0000-0003-2402-4157
Stefan KnappInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID http://orcid.org/0000-0001-5995-6494
Dafydd R OwenPfizer Research and Development, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3106-7809
Rachel HardingStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-1134-391X
Matthieu SchapiraStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-1047-3309
Peter J BrownStructural Genomics Consortium, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-8454-0367
Vijayaratnam SanthakumarStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-7001-557X
Suzanne AcklooStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-9696-1839
Cheryl H ArrowsmithStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-4971-3250
Aled M EdwardsStructural Genomics Consortium, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-4782-6016
Hui PengDepartment of Chemistry, University of Toronto, Toronto, ON, Canada. hui.peng@utoronto.ca.ORCID http://orcid.org/0000-0002-2000-1647
Levon HalabelianStructural Genomics Consortium, University Health Network, Toronto, ON, Canada. l.halabelian@utoronto.ca.ORCID http://orcid.org/0000-0003-4361-3619

Funding

TREAT AD Structural Biology CoreU54AG065187 · NIA · EMORY UNIVERSITY · PI Gregory W Carter, ALLAN I LEVEY · 2019 to 2026
$69.7M
NIA NIH HHS U54 AG065187
6 · The paper itself

Abstract

We report an enantioselective protein affinity selection mass spectrometry screening approach (E-ASMS) that enables the detection of weak binders, informs on selectivity, and generates orthogonal confirmation of binding. After method development with control proteins, we screen 31 human proteins against a designed library of 8,217 chiral compounds. We identify 16 binders to 12 targets, including many proteins predicted to be "challenging to ligand", and confirm their interactions through orthogonal biophysical assays. Seven binders to six targets display enantioselective binding, with K

Indexed as

Mass SpectrometryProteinsCrystallography, X-RayHumansLigandsProtein BindingStereoisomerismLigandsProteins

Identifiers

PMID41407727
PMCPMC12816581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.